Cécile Tomowiak
YOU?
Author Swipe
View article: 264 | CD3XCD20 BISPECIFIC ANTIBODIES IN TRANSFORMED WALDENSTRÖM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA
264 | CD3XCD20 BISPECIFIC ANTIBODIES IN TRANSFORMED WALDENSTRÖM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA Open
View article: Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study Open
View article: Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia Open
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. The results of the REMODEL trial demonstrated interesting efficacy in a high-ris…
View article: Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia Open
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. The results of the REMODEL trial showed interesting efficacy in a high-risk geno…
View article: Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group
Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group Open
Introduction: Hairy-cell leukemia (HCL) is a rare B-cell chronic lymphoproliferative disorder (B-CLPD), whose favorable prognosis has changed with the use of purine nucleoside analogs (PNAs), such as cladribine (CDA) or pentostatin (P). Ho…
View article: Bleeding risk with concurrent use of anticoagulants and ibrutinib: A population‐based nested case‐control study
Bleeding risk with concurrent use of anticoagulants and ibrutinib: A population‐based nested case‐control study Open
Summary Data regarding the safety of co‐administration of ibrutinib with anticoagulants in real‐life settings are scarce. Using a nationwide database, we conducted a nested case‐control study in a cohort of new users of ibrutinib to assess…
View article: Hairy cell leukemia with isolated bone lesions
Hairy cell leukemia with isolated bone lesions Open
Key Clinical Message 18 F‐FDG PET/CT has clinical relevance in HCL at diagnosis and for the follow‐up of patients treated, especially in case of atypical presentations such as bone involvements (which are probably underestimated) and poor …
View article: A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial Open
In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07 …
View article: Data from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Data from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia Open
Purpose: TP53 is a tumor-suppressor gene that functions as a regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little is k…
View article: Supplementary Table 1, Supplementary Figures 1-4 from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Supplementary Table 1, Supplementary Figures 1-4 from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia Open
Table S1. Genomic characteristics of WM with TP53 aberration; Figure S1: Delineation of 17p minimal deleted region detected by SNP array in Waldenstrom's macroglobulinemia; Figure S2. (1) Nutlin-3a effects on WM cells. Impact of nutlin-3a …
View article: Supplementary Table 1, Supplementary Figures 1-4 from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Supplementary Table 1, Supplementary Figures 1-4 from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia Open
Table S1. Genomic characteristics of WM with TP53 aberration; Figure S1: Delineation of 17p minimal deleted region detected by SNP array in Waldenstrom's macroglobulinemia; Figure S2. (1) Nutlin-3a effects on WM cells. Impact of nutlin-3a …
View article: Data from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Data from <i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia Open
Purpose: TP53 is a tumor-suppressor gene that functions as a regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little is k…
View article: Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis Open
Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). We characterize 58 primary human RS samples by genome-wide DNA methylation and…
View article: Hairy cell leukemia with isolated bone lesions
Hairy cell leukemia with isolated bone lesions Open
Bone lesions are rarely reported in Hairy Cell Leukemia (HCL). We report two BRAFV600E mutated HCL patients presented bone lesions at foreground, poor bone marrow involvement and the important role 18F-FDG PET/CT played in their management…
View article: Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study) Open
International audience
View article: Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment
Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment Open
Histological transformation (HT) to an aggressive lymphoma results from a rare evolution of Waldenström macroglobulinemia (WM). A higher incidence of transformation events has been reported in MYD88 wild-type WM patients. HT in WM can be h…
View article: Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine
Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine Open
Preservation of fertility has become a growing concern in young females with Hodgkin lymphoma (HL). However, the rate of pregnancy after the current most frequently prescribed ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dar…
View article: Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy
Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy Open
International audience
View article: Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients Open
Hairy cell leukemia (cHCL) patients have, in most cases, a specific clinical and biological presentation with splenomegaly, anemia, leukopenia, neutropenia, monocytopenia and/or thrombocytopenia, identification of hairy cells that express …
View article: Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?
Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia? Open
In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). In follicular lymphoma and other B‐cell and T‐cell lymphomas, disease progression within 24 month…
View article: High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia Open
Histologicaltransformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a rare event in Waldenström macroglobulinemia (WM) and is associated with a poor prognosis.1-4 It confers an inferior outcome compared with WM patients without HT.…
View article: Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia Open
Immunocompromised individuals such as patients with chronic lymphocytic leukemia (CLL) are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate severe acute respiratory syndrome coronavirus 2 (SAR…
View article: Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an ongoing global pandemic. Phase III trials have demonstrated excellent efficacies of mRNA vaccines against SARS-CoV-2 in large population studies (Baden LR, …
View article: Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database Open
As ibrutinib has become a standard of care in B-cell malignancies in monotherapy or in combination with other agents, definition of its safety profile appears essential. The aim of this study was to further characterize the safety profile …
View article: Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization Open
International audience
View article: Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia Open
We present the results of a phase 2 study evaluating the combination of obinutuzumab + idelalisib in relapsed/refractory (R/R) Waldenström macroglobulinemia (WM). The goal was to determine the safety and efficacy of a fixed-duration chemot…
View article: BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia Open
Conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL), such as cytotoxic chemotherapy and alemtuzumab, have limited efficacy and considerable toxicity. Several novel agent classes have demonstrated preclinical act…
View article: Étude CLL14 : l’avantage est donné aux thérapies ciblées dans la leucémie lymphoïde chronique en première ligne des patients unfit !
Étude CLL14 : l’avantage est donné aux thérapies ciblées dans la leucémie lymphoïde chronique en première ligne des patients unfit ! Open
View article: A prognostic index predicting survival in transformed Waldenström macroglobulinemia
A prognostic index predicting survival in transformed Waldenström macroglobulinemia Open
Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) and is usually associated with a poor prognosis. The objective of this study was to develop and valid…
View article: A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial Open
Trials assessing first-line, fixed-duration approaches in chronic lymphocytic leukemia (CLL) are yielding promising activity, but few long-term data are available. We report follow-up data from a phase 2 trial (ICLL07 FILO) in previously u…